Insulin-like growth factor-I (IGF-I) in human hepatoma cells (HEP-G2) has, in addition to its effect on cell growth, shortterm metabolic effects acting through its own receptor. We have demonstrated that normal human hepatocytes, compared with HEP-G2 cells, have virtually no IGF-I binding sites. Because the rate of growth is the major difference between the hepatoma and the normal liver, we asked if normal liver might express IGF-I binding sites under physiologic growth conditions. Indeed, whereas adult rat hepatocytes have low IGF-I binding sites similar to those in human liver, hepatocytes from regenerating liver after 3 d subtotal hepatectomy have an approximately sixfold increase (P < 0.005) and those from fetal rat liver a -12-fold increase (P < 0.005), to levels comparable to those in the HEP-G2 cells. The specificity of 125I IGF-I binding to its receptor was demonstrated by competition studies with monoclonal antibodies directed toward the IGF-I and the insulin receptors, with unlabeled IGF-I and insulin and by affinity labeling experiments. Thus, if IGF-I has any shortterm metabolic functions in the adult human liver, it is not through interaction with its own receptor. Autocrine regulation by IGF-I of liver growth appears possible since IGF-I binding sites are expressed under pathological and physiological conditions of growth. The mechanism that couples these two phenomena remains to be elucidated.
Introduction
Insulin and the type-I insulin-like growth factor (IGF-I)' exhibit a similar spectrum of biological activities and have a high degree of sequence homology (1, 2) . The primary event in the action of IGF-I on target cells, similar to that of insulin, appears to be the binding to specific receptors on the cell surface (2-4). The IGF-I receptor consists of heterotetrameric disulfide-linked subunits, the structure of which closely resembles that of the insulin receptor (5, 6) . Given these similarities, it is not unexpected that insulin can react with the IGF-I receptor and that IGF-I can react with the insulin receptor (7) . Each hormone can react with the other's binding sites, but with relatively reduced affinities (7) . We have developed a method to isolate insulin-responsive human hepatocytes from 1-2 g intraoperative liver biopsy to study insulin action and resistance in man (8) . Thus, it is imperative to study IGF-I binding and action in human liver to determine whether insulin-stimulated biological events are mediated through the insulin receptor or are due to IGF-I receptor occupation. This question is particularly relevant as it has recently been shown in the fetal rat hepatocytes that IGF-I was 20 times more potent than insulin in stimulating glycogen synthesis (9, 10) . Similarly, in the human hepatoma cell line (HEP-G2), IGF-I stimulates glycogen synthesis, and insulin over 100 pM appears to stimulate insulin action through interaction with the IGF-I binding sites (1 1).
Methods
Materials. Recombinant IGF-I was purchased from AMGen Biologicals, Thousand Oak, CA, and 125I IGF-I (2,000 Ci/mmol) from Amer- Isolated hepatocytes. Human hepatocytes were isolated as previously described (8) . The donors were a 35-yr-old female with morbid obesity (weight 97 kg, height 155 cm) and without diabetes mellitus (fasting plasma glucose, 93 mg/dl; fasting plasma insulin, 31 tU/ml; peak plasma insulin during intravenous glucose tolerance test, 184 gU/ml; and kg rate 1.4%/min glucose disappearance) and a 50-yr-old female with morbid obesity (95 kg, height 165 cm) and untreated non-insulin-dependent diabetes mellitus (fasting plasma glucose, 194 mg/dl; fasting plasma insulin, 38 uU/ml; peak plasma insulin during intravenous glucose tolerance test, 46 AU/ml; and kg rate 0.6%/min glucose disappearance) undergoing an elective gastric bypass. The subjects underwent surgery in the morning after an overnight fast. No glucose was given intravenously before the liver biopsy. As soon as the abdomen was opened and explored to demonstrate no contraindication to the surgical procedure, a 1-2-g liver biopsy was obtained from the left lobe. Written consent was obtained from all patients after they were informed about the nature and potential risks of the study.
HEP-G2 cells were obtained from Dr. B. Knowles, Wistar Institute, Philadelphia, PA. The cells were cultured as described by Knowles et Rat hepatocytes were isolated, as we have previously described (14) , from adult normal male Sprague-Dawley rats, from regenerating liver after 1-4 d subtotal hepatectomy as described by Blachard et al. (15) , and from 20 d gestation fetal Sprague-Dawley rats as described by Sinha et al. (16) .
Liver plasma membranes. Liver plasma membranes were prepared from six male Sprague-Dawley rats on the third day after subtotal hepatectomy and their sham-operated, pair-fed controls, from three 20-d gestational fetal Sprague-Dawley rats, and from three human brain-dead organ donors who had no previous history ofany metabolic disease. The liver tissue was homogenized in 1 mM NaHCO3 buffer, containing 0.5 mM CaCl2 (pH 7.5) as described by Ray (17), with the addition of 2 AM leupeptin, 2 AM pepstatin, 1 mM penylmethylsulfonyl fluoride, 0.1 mg/ml bacitracin, and 1,000 U/ml aprotinine. The plasma membranes were isolated by the aqueous two-phase polymer method of Lesko et al. (18) with minor modifications (8) . The membranes were suspended in 50 mM Hepes buffer (pH 7.4) and kept at -70°C until they were used.
125I IGF-I binding. Hepatocytes (-1 X 106 cells/ml) were suspended in Hanks'-Hepes buffer (pH 7.4) containing 8 mM glucose and 10 mg/ml BSA. HEP-G2 cells were either detached from the culture plates and suspended as described, or studied while adhered to 35 Initial experiments were performed to determine optimal conditions under which to study IGF-I binding. At 20°C, maximum IGF-I binding plateaued from 60 to 240 min. Thus, the binding studies described in this report were performed at 20°C for 120 or 180 min. Under these conditions, nonspecific binding and ligand degradation were < 20% of total IGF-I binding and free IGF-I in the incubation medium, respectively. Furthermore, IGF-I binding was linear over a range of 0.5-2 x 106 isolated hepatocytes and 100-250 Mg liver plasma membrane.
Affinity labeling ofthe IGF-I receptor. Following optimal 1251 IGF-I binding in the absence and presence of unlabeled IGF-I (1 X 10-9 M to I X 10-6 M) and unlabeled insulin (1 X l0-9 M to I X 10-6 M) to liver plasma membranes as described in the preceding section, the 1251I IGF-I receptor complex was covalently cross-linked with 0.5 mM disuccinimidyl suberate for 10 min at 4°C by the method of Pilch and Czech (19) . The reaction was stopped by adding 50 mM Tris HCI (pH 7.0) containing 1% SDS, 0.005 bromophenol blue, 2% glycerol, and 50 mM dithiothreitol and boiling for 3 min. Polyacrylamide gel electrophoresis was performed according to the method of Laemmli (20) in 7.5% polyacrylamide slab gels. Then the gels were stained, destained, dried, and autoradiographed with Kodak X-OMAT film using lightening plus-screen.
12-I insulin binding. 25I insulin binding was performed in liver plasma membranes from the experimental groups as previously described (8 concentration of monoclonal antibodies to the insulin receptors had no effect.
Thus, a tissue from the same species under pathological conditions expresses a different amount of IGF-I binding sites. The major distinction between HEP-G2 cells and normal liver is the former's pathological growth rate and the fact that it has been maintained in culture. We then asked if normal liver could express IGF-I binding under physiological growth conditions. Fig. 3 attempts to answer this question. Freshly isolated hepatocytes from fetal rat liver have as much specific 125I
IGF-I binding as did the HEP-G2 cells. I251GF-I binding in fetal rat hepatocytes was statistically higher (P < 0.01-0.005) than the other experimental groups shown in Fig. 3 . As previously shown by Massague and Czech in liver plasma membranes (7), freshly isolated hepatocytes from adult rat liver have extremely low, if any, IGF-I binding sites. Furthermore, IGF-I binding remained < 1% in primary cultures of adult rat hepatocytes for up to 48 h. However, freshly isolated hepatocytes from regenerating adult rat liver after subtotal hepatectomy, have a significant increase in IGF-I binding that is maintained for up to 4 d when compared with normal adult hepatocytes (day 1-2, P < 0.05; day 3, P < 0.005; day 4 P < 0.025). Insulin-like growth factor-I binding in liver after 3 d subtotal hepatectomy is higher than that from day 4 (P < 0.025), but it is not different from that from day 1-2; likewise, day 1-2 is not statistically different from that from day 4.
The advantages of using isolated hepatocytes is that they allow the selection of parenchymal cells. This is particularly true in the case of fetal liver, which contains a significant amount of hematopoetic tissue. A potential pitfall of this approach, however, is that the methodologies necessary to isolate human hepatocytes, adult rat hepatocytes, and fetal rat hepatocytes are significantly different, particularly since each requires a different type of collagenase. Thus, the changes observed could be due to differences in survival of the IGF-I receptor to a specific cell isolation procedure or collagenase type. To address this question, we prepared liver plasma membranes to study IGF-I binding, not from isolated hepatocytes, but from the liver. Furthermore, we introduced a shamoperated, control pair fed with the hepatectomized rats, since the increase in IGF-I binding in the regenerating liver could have been due to stress or nutritional factors. 18- 4 shows the data generated in liver plasma membranes. Fetal rat liver has statistically higher (P < 0.005) IGF-I binding when compared with liver from each of the other groups. Adult rat liver from 3 d after subtotal hepatectomy also has higher (P < 0.05) IGF-I binding than the respective sham-operated pair fed control. IGF-I binding in this adult rat control was no different from that found in adult human liver. The inset in Fig. 4 is a Scatchard plot of the data that suggests that the changes in IGF-I binding are mainly due to differences in the number of binding sites. However, since insulin and IGF-I cross-react with each others' receptor and it is known that there are differences in 125I insulin binding among fetal rat liver (16) , regenerating liver (21), and adult liver, 1251 insulin binding was also measured in the same liver plasma membrane as shown in Fig. 5 . It can be seen that the regenerating liver had approximately a half-fold increase in insulin binding when compared with the control; this difference was significant (P < 0.05) at the three lowest concentrations of insulin used, whereas the increase in IGF-I binding was approximately threefold (Fig. 4) . Likewise, insulin binding in the human liver was similar to that in the rat liver, but IGF-I binding was extremely low. The increase in insulin binding in the fetal liver was approximately fourfold, whereas it was sixfold for IGF-I binding compared with the adult rat liver (Fig. 4) . Thus, the changes in insulin binding observed cannot explain the data on IGF-I binding, particularly considering the limited cross-reactivity of insulin with the IGF-I receptor and of IGF-I with the insulin receptors (7). However, it should be recognized that, although to varying degrees, insulin and IGF-I binding are increased in regenerating and fetal rat liver. This is not surprising since both hormones exhibit a similar spectrum of biological activities and it is not a universal finding for other receptors (21) .
To exclude the possibility that 1251 IGF-I was interacting to a significant degree with the type II IGF receptor, we affinity labeled 1251IGF-I to the plasma membranes. Insulin (ng/ml) BRL 3A2 rat liver cells (23) , rat hepatoma HTC cells (24) , fetal liver (25) , and regenerating rat liver that have rapid rates of growth express IGF-I binding sites. A notable exception, perhaps, is the rat H-35 hepatoma, which does not have IGF-I receptors (7), although IGF-I actions are mediated throughout the insulin recpptors (26) .
The liver is, however, the source of IGF-I, whether or not IGF-I receptors are present (27, 28) . Thus, it is possible that once IGF-I receptors are expressed in the cell membrane, autocrine interaction of the hormone with its own receptor stimulates liver proliferation. Under regulated growth conditions, this initial step might be followed by down-regulation of the IGF-I receptors, an event that might not be operative under pathological growth conditions. This is consistent with our observation that incubation ofHEP-G2 cells with monoclonal antibodies to the IGF-I receptors decreases cell proliferation (unpublished data). Furthermore, Unterman and Phillips (29) have recently demonstrated that IGF-I production by the regenerating rat liver is enhanced. In vitro studies also have shown that IGF-I stimulates the protein synthesis (30) and proliferation (31) of hepatocytes. Consistent with this notion is the finding that hypophysectomy retards hepatic regeneration (32) , which can be improved by the administration of growth hormone.
IGF-I binding sites have been described in several human and nonhuman tissues (2-7, 11, 22, 33-40) . The biological significance of the short-term effect of IGF-I on metabolic function in physiology and pathology in man is unclear at this time. If IGF-I plays any role, however, in the adult human liver, it is by interacting with other binding sites, because IGF-I binding is not present.
